A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

NCT07037862

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Entrada Therapeutics, Inc.
Enrollment	24 participants

Key Eligibility Criteria

Inclusion (6)

- Genetic diagnosis of Duchenne muscular dystrophy (DMD) and confirmed pathologic variant in the dystrophin gene amenable to exon 44 skipping as reviewed by a central genetic counselor.
- Assigned male at birth with clinical signs compatible with Duchenne muscular dystrophy as determined by the investigator.
- Part A: 4-20 years of age, inclusive.
- Ambulatory Status Part A: ambulatory with a Performance of the Upper Limb v2.0 (PUL 2.0) Entry as per protocol at Screening
- Adequate muscle for obtaining tissue biopsy as assessed by the investigator.

... and 1 more (see full listing online)

Exclusion (13)

- Any significant concomitant medical condition that might interfere with the ability to comply with protocol requirements.
- Has an acute illness within 4 weeks prior to the first dose of study drug which may interfere with study measurements or jeopardize participant's safety.
- Use of the following medications:
- Prior treatment with any exon skipping therapy at any time
- Prior treatment with any gene therapy at any time

... and 8 more (see full listing online)

Locations (14 total)

University Hospital Gent, Ghent, Belgium
UZ Leuven, Leuven, Belgium
Centre Hospitalier Régional de la Citadelle, Liège, Belgium
... and 11 more locations